Perkovic, Vlado

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

Perkovic, V., Heerspink, H. L., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M. E., Hamet, P., Marre, M., et al. (2013) · Kidney International

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 316

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial

Mahaffey, K. W., Jardine, M. J., Bompoint, S., Cannon, C. P., Neal, B., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., et al. (2019) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 291

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program

Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Desai, M., Li, Q., Deng, H., et al. (2018) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 257

Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER

Shaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 255

Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

Arnott, C., Li, Q., Kang, A., Neuen, B. L., Bompoint, S., Lam, C. S. P., Rodgers, A., Mahaffey, K. W., Cannon, C. P., Perkovic, V., et al. (2020) · Journal of the American Heart Association

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 247

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

Rossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., et al. (2023) · Nephrology Dialysis Transplantation

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 242

Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON

Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., et al. (2016) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 240

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics

Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., et al. (2017) · American Journal of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 234

Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes

Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Ways, K., Desai, M., Shaw, W., Capuano, G., Alba, M., et al. (2015) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 233

Effects of the Mediterranean Diet on Cardiovascular Outcomes—A Systematic Review and Meta-Analysis

Liyanage, T., Ninomiya, T., Wang, A., Neal, B., Jun, M., Wong, M. G., Jardine, M., Hillis, G. S., & Perkovic, V. (2016) · PLOS ONE

Nutritional Studies and DietCardiovascular Health and Risk Factors

Cited by 210

Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease: A Systematic Review and Meta-analysis

Palmer, S. C., Di Micco, L., Razavian, M., Craig, J. C., Perkovic, V., Pellegrini, F., Copetti, M., Graziano, G., Tognoni, G., Jardine, M., et al. (2012) · Annals of Internal Medicine

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 204

Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis

Kotwal, S., Jun, M., Sullivan, D., Perkovic, V., & Neal, B. (2012) · Circulation: Cardiovascular Quality and Outcomes

Fatty Acid Research and HealthNutritional Studies and Diet

Cited by 201

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

Mann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., et al. (2024) · Nature Medicine

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 200

Corticosteroid therapy in IgA nephropathy

Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D. W., Woodward, M., Levin, A., Zhang, H., & Wang, H. (2012) · Journal of the American Society of Nephrology

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 190

Effects of Fibrates in Kidney Disease

Jun, M., Zhu, B., Tonelli, M., Jardine, M. J., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., & Perkovic, V. (2012) · Journal of the American College of Cardiology

Chronic Kidney Disease and DiabetesLipoproteins and Cardiovascular Health

Cited by 189

Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE Trial

Oshima, M., Neuen, B. L., Li, J., Perkovic, V., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., Mahaffey, K. W., et al. (2020) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 176

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( CANVAS‐R ): A randomized, placebo‐controlled trial

Neal, B., Perkovic, V., Matthews, D. R., Mahaffey, K. W., Fulcher, G., Meininger, G., Erondu, N., Desai, M., Shaw, W., Vercruysse, F., et al. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 174

Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis

Neuen, B. L., Fletcher, R. A., Heath, L., Perkovic, A., Vaduganathan, M., Badve, S. V., Tuttle, K. R., Pratley, R., Gerstein, H. C., Perkovic, V., et al. (2024) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 168

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Oshima, M., Jardine, M. J., Agarwal, R., Bakris, G., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., et al. (2021) · Kidney International

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 166

Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA

McGuire, D. K., Alexander, J. H., Johansen, O. E., Perkovic, V., Rosenstock, J., Cooper, M. E., Wanner, C., Kahn, S. E., Toto, R. D., Zinman, B., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 164

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

Li, J., Woodward, M., Perkovic, V., Figtree, G. A., Heerspink, H. J. L., Mahaffey, K. W., de Zeeuw, D., Vercruysse, F., Shaw, W., Matthews, D. R., et al. (2020) · JACC: Heart Failure

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 144

Isolated Low Levels of High-Density Lipoprotein Cholesterol Are Associated With an Increased Risk of Coronary Heart Disease: An Individual Participant Data Meta-Analysis of 23 Studies in the Asia-Pacific Region

Huxley, R. R., Barzi, F., Lam, T. H., Czernichow, S., Fang, X., Welborn, T., Shaw, J., Ueshima, H., Zimmet, P., Jee, S. H., et al. (2011) · Circulation

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 144

The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study

Jun, M., James, M. T., Manns, B. J., Quinn, R. R., Ravani, P., Tonelli, M., Perkovic, V., Winkelmayer, W. C., Ma, Z., Hemmelgarn, B. R., et al. (2015) · BMJ

Atrial Fibrillation Management and OutcomesPharmaceutical Practices and Patient Outcomes

Cited by 143

Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial

Bakris, G., Oshima, M., Mahaffey, K. W., Agarwal, R., Cannon, C. P., Capuano, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., et al. (2020) · Clinical Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 142